These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11804276)

  • 1. Technology evaluation: MG-98, MethylGene.
    Zhang Z
    Curr Opin Mol Ther; 2001 Dec; 3(6):599-604. PubMed ID: 11804276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GTI-2040. Lorus Therapeutics.
    Orr RM
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
    Morse MA
    Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
    Tamm I
    Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genasense (Genta Inc).
    Banerjee D
    Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GTI-2501. Lorus Therapeutics.
    Tu GC; Tu X
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1467-70. PubMed ID: 11890367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.
    Vallières L
    IDrugs; 2009 Jul; 12(7):445-53. PubMed ID: 19579166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GEM-231 (Hybridon).
    Blay J
    IDrugs; 2000 Sep; 3(9):1075-80. PubMed ID: 16049867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technology evaluation: GEM-231, Hybridon Inc.
    Blay J
    Curr Opin Mol Ther; 2000 Aug; 2(4):468-72. PubMed ID: 11249779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technology evaluation: GEM-231, Hybridon.
    Yeung PK
    Curr Opin Mol Ther; 2003 Jun; 5(3):315-20. PubMed ID: 12870443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technology evaluation: AVI-4126, AVI BioPharma.
    Stephens AC
    Curr Opin Mol Ther; 2004 Oct; 6(5):551-8. PubMed ID: 15537057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INGN-201. Introgen Therapeutics.
    Brukner I
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1776-85. PubMed ID: 11892946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. British Biotech and MethylGene sign agreement on Phase II antisense drug.
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):6. PubMed ID: 12113069
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
    Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
    J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.